A5054546870- Gut microbiota and health
- Liver Disease Diagnosis and Treatment
- Diet and metabolism studies
- Gastroesophageal reflux and treatments
- Cardiac, Anesthesia and Surgical Outcomes
- Bariatric Surgery and Outcomes
- Global Health Workforce Issues
- Adolescent and Pediatric Healthcare
- Enhanced Recovery After Surgery
- Food Security and Health in Diverse Populations
- Pneumonia and Respiratory Infections
- Organ Transplantation Techniques and Outcomes
- Helicobacter pylori-related gastroenterology studies
- Liver Disease and Transplantation
- Clinical Nutrition and Gastroenterology
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Clostridium difficile and Clostridium perfringens research
King's College Hospital
2024
King's College Hospital NHS Foundation Trust
2015-2023
Foundation for Liver Research
2022
<h3>Objective</h3> Proton pump inhibitors (PPIs) are drugs used to suppress gastric acid production and treat GI disorders such as peptic ulcers gastro-oesophageal reflux. They have been considered low risk, widely adopted, often over-prescribed. Recent studies identified an increased risk of enteric other infections with their use. Small possible associations between PPI use microbiota, but this has yet be carried out on a large population-based cohort. <h3>Design</h3> We investigated the...
The human gut microbiome has been associated with many health factors but variability between studies limits exploration of effects them. Gut microbiota profiles are available for >2700 members the deeply phenotyped TwinsUK cohort, providing a uniform platform such comparisons. Here, we present association analyses 38 common diseases and 51 medications within cohort. We describe several novel associations, highlight associations across multiple diseases, determine which have greatest...
Background: Chronic liver disease (CLD) is a progressive condition that, in its advanced stages, leads to cirrhosis with related clinical complications, and can lead acute-on-chronic failure (ACLF) - syndrome marked by critical illness, multi-organ dysfunction high mortality. Systemic inflammation ACLF occur without overt infection, indicating alternative pathways of immune activation microbial translocation. Intestinal perturbations, bacterial translocation, the resulting systemic are...
As the global prevalence of chronic liver disease continues to rise, need determine which patients will develop end-stage and require transplantation is increasingly important. However, current prognostic models perform sub-optimally. We aim microRNA profiles associated with clinical decompensation mortality/transplantation within 1 year. examined expression in plasma samples from across spectrum cirrhosis (n = 154), acute failure (ALF) 22), sepsis 20) healthy controls (HC) 20). demonstrated...
<h3>Introduction</h3> Liver disease is the second leading cause of work years lost in Europe creating a significant burden disease.<sup>1</sup> With an ageing, multi-morbid population we now manage increasingly complex cohorts patients with advanced chronic liver (ACLD), necessitating multi-disciplinary team (MDT) approach to optimise care. A regional ACLD MDT was initiated facilitate joint discussions regarding TIPSS/transplant assessment as well advance care planning (ACP). Since...
<h3>Background/Aims</h3> Decompensated cirrhosis (DC) is characterised by altered gut microbiome composition and function, intestinal barrier failure immune dysfunction inflammation, all hypothesised to contribute increased risks of infection hepatic decompensation. A live, multi-strain, aqueous probiotic suspension (Symprove™) that has undergone rigorous efficacy testing in other diseases including ulcerative colitis (Bjarnason et al, 2019)<sup>1</sup> diverticular disease (Kvasnovsky...